Arcturus Therapeutics Holdings Inc. · NASDAQ:ARCT

Arcturus Therapeutics — Technical Presentation (October 2025)

10 slides from Arcturus Therapeutics's technical presentation, Oct 22, 2025

  1. Slide 1: LUNAR-CF (ARCT-032) Interim Phase 2 Results

    - — kk a ! nn a” LUNAR-CF (ARCT-032) INTERIM PHASE 2 RESULTS Inhaled mRNA Therapeutic Candidate for Cystic Fibrosis therapeutics

  2. Slide 2: Cohort 2: FEV1 Summary Tables

    Cohort 2: FEV1 Summary Tables Table 1. Relative Percent Change (%) From Protocol Defined Baseline or Exploratory Baseline in FEV1 Relative Percent Change (%) from Protocol Defined | Relative Percent Change (%) From Exploratory Observed FEV] [L] Baseline in FEV1 Baseline in FEV] Subject Screening | D

  3. Slide 3: Cohort 2: FEV1 Exploratory Data Analysis

    Cohort 2: FEV1 Exploratory Data Analysis DES j Subject Number |Dose(mg)| Relative AppFEV1@d42 | Absolute AppFEV1 @ d42 5 10 74 49 3 10 6.6 45 2 10 3.5 3.1 6 10 3.0 2.5 10 44 -2.8 1 10 -11.6 -9.9 Initial FEV1 data analysis per protocol in the 6 Class | subjects comparing FEV1 on the first day of trea

  4. Slide 4: Cohort 2: FEV1 Exploratory Data Analysis

    x ARCTURUS Cohort 2: FEV1 Exploratory Data Analysis serene Study ARCT-032.02, Cohort 2 10mg) : Plot of Relative Percent Change (0) from Exploratory Baseline in FEV by Study Day Follow up Period Average 5.1% ‘Subject ID |—e— tomg1004-0001 10g 100-000 ~ ag 106-0002 |—-2—- somg1008-0002 ae — song 1008-

  5. Slide 5: Cohort 2: Mucus Reduction Summary

    ARCTURUS Cohort 2: Mucus Reduction Summary Acar j Subject Dose | Number of Mucus Plugs Mucus Volume (mL) Number (mg) % Change @ Day 28 % Change @ Day 28 2 10 =38.5% ~67.4% 10 -34.9% “27.5% 6 10 -28.5% 29.5% 5 10 “9.1% 6.1% 3 10 23.8% 9.1% a 10 25.6% 60.9% 4 out of 6 subjects in Cohort 2 exhibited Mu

  6. Slide 6: Lung Images Provided by Thirona Utilizing FDA 510(k)-Cleared AI Analysis Technology

    Lung Images Provided by thir=na JX AgcTURUS y utilizing FDA 510(k)-cleared Al Analysis Technology somes HRCT scans were analyzed using Thirona Al analysis: FDA 510(k)-cleared technology capable of using Al to automatically segment the pulmonary segments and subsegments in the internal anatomy of the

  7. Slide 7: ARCTURUS'

    Cohort 2: Patient 2 ARCTURUS' Day 0 Day 28 AX © 2025 Arcturus Therapeutics, Inc. 7

  8. Slide 8: AC

    Cohort 2: Patient 4 AC © 2025 arcturus Therapeutics, Inc. 8

  9. Slide 9: AC

    Cohort 2: Patient 5 AC ©2025 arcturus Therapeutics, Inc. 9

  10. Slide 10: ARCTURUS

    Cohort 2: Patient 6 ARCTURUS Day 0 AX © 2025 Arcturus Therapeutics, Inc. 10

Arcturus Therapeutics Holdings — Technical Presentation (October 2025) on 6ix